These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16817978)

  • 1. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis.
    Lequerré T; Gauthier-Jauneau AC; Bansard C; Derambure C; Hiron M; Vittecoq O; Daveau M; Mejjad O; Daragon A; Tron F; Le Loët X; Salier JP
    Arthritis Res Ther; 2006; 8(4):R105. PubMed ID: 16817978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients.
    Lindberg J; af Klint E; Catrina AI; Nilsson P; Klareskog L; Ulfgren AK; Lundeberg J
    Arthritis Res Ther; 2006; 8(6):R179. PubMed ID: 17134501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential gene expression profiles may differentiate responder and nonresponder patients with rheumatoid arthritis for methotrexate (MTX) monotherapy and MTX plus tumor necrosis factor inhibitor combined therapy.
    Oliveira RD; Fontana V; Junta CM; Marques MM; Macedo C; Rassi DM; Passos GA; Donadi EA; Louzada-Junior P
    J Rheumatol; 2012 Aug; 39(8):1524-32. PubMed ID: 22753658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-treatment whole blood gene expression is associated with 14-week response assessed by dynamic contrast enhanced magnetic resonance imaging in infliximab-treated rheumatoid arthritis patients.
    MacIsaac KD; Baumgartner R; Kang J; Loboda A; Peterfy C; DiCarlo J; Riek J; Beals C
    PLoS One; 2014; 9(12):e113937. PubMed ID: 25504080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis.
    Thomson TM; Lescarbeau RM; Drubin DA; Laifenfeld D; de Graaf D; Fryburg DA; Littman B; Deehan R; Van Hooser A
    BMC Med Genomics; 2015 Jun; 8():26. PubMed ID: 26036272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene profiling predicts rheumatoid arthritis responsiveness to IL-1Ra (anakinra).
    Bansard C; Lequerré T; Derambure C; Vittecoq O; Hiron M; Daragon A; Pouplin S; Daveau M; Boyer O; Tron F; Le Loët X; Salier JP
    Rheumatology (Oxford); 2011 Feb; 50(2):283-92. PubMed ID: 21059672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Biomarkers for Predicting Infliximab Response in Rheumatoid Arthritis: A Systematic Bioinformatics Analysis.
    Huang QL; Zhou FJ; Wu CB; Xu C; Qian WY; Fan DP; Cai XS
    Med Sci Monit; 2017 Apr; 23():1849-1855. PubMed ID: 28413214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis.
    Kapoor SR; Filer A; Fitzpatrick MA; Fisher BA; Taylor PC; Buckley CD; McInnes IB; Raza K; Young SP
    Arthritis Rheum; 2013 Jun; 65(6):1448-56. PubMed ID: 23460124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment.
    van Baarsen LG; Wijbrandts CA; Rustenburg F; Cantaert T; van der Pouw Kraan TC; Baeten DL; Dijkmans BA; Tak PP; Verweij CL
    Arthritis Res Ther; 2010; 12(1):R11. PubMed ID: 20096109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders.
    Oswald M; Curran ME; Lamberth SL; Townsend RM; Hamilton JD; Chernoff DN; Carulli J; Townsend MJ; Weinblatt ME; Kern M; Pond CM; Lee A; Gregersen PK
    Arthritis Rheumatol; 2015 Feb; 67(2):344-51. PubMed ID: 25371395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis.
    Lindberg J; Wijbrandts CA; van Baarsen LG; Nader G; Klareskog L; Catrina A; Thurlings R; Vervoordeldonk M; Lundeberg J; Tak PP
    PLoS One; 2010 Jun; 5(6):e11310. PubMed ID: 20593016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
    van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP
    Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
    Maini R; St Clair EW; Breedveld F; Furst D; Kalden J; Weisman M; Smolen J; Emery P; Harriman G; Feldmann M; Lipsky P
    Lancet; 1999 Dec; 354(9194):1932-9. PubMed ID: 10622295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.
    Choi IY; Gerlag DM; Herenius MJ; Thurlings RM; Wijbrandts CA; Foell D; Vogl T; Roth J; Tak PP; Holzinger D
    Ann Rheum Dis; 2015 Mar; 74(3):499-505. PubMed ID: 24297376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis.
    Takeuchi T; Miyasaka N; Tatsuki Y; Yano T; Yoshinari T; Abe T; Koike T
    Ann Rheum Dis; 2011 Jul; 70(7):1208-15. PubMed ID: 21478189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade.
    Smolen JS; Han C; van der Heijde DM; Emery P; Bathon JM; Keystone E; Maini RN; Kalden JR; Aletaha D; Baker D; Han J; Bala M; St Clair EW;
    Ann Rheum Dis; 2009 Jun; 68(6):823-7. PubMed ID: 18593759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
    Lipsky PE; van der Heijde DM; St Clair EW; Furst DE; Breedveld FC; Kalden JR; Smolen JS; Weisman M; Emery P; Feldmann M; Harriman GR; Maini RN;
    N Engl J Med; 2000 Nov; 343(22):1594-602. PubMed ID: 11096166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.